Cilcare
Hatim Bekkali is an experienced professional with a strong background in business development and systems management. Currently serving as an Investor at Mobula Labs since May 2023, and at Mr Suricate and Bricks.co since November 2022 and June 2022, respectively. Bekkali has been a key figure at SYLOÉ since March 2005, holding positions as Business Developer, Directeur Général, and Founder. Under Bekkali's leadership, SYLOÉ, part of the DRI group since March 2019, specializes in advanced Linux expertise and innovative solutions for security and information systems engineering. Previous experience includes serving as System Information Manager at Soamai, where Bekkali oversaw the development and management of a robust internal network. Bekkali’s educational credentials include advanced degrees from Pierre and Marie Curie University and Université de Montréal, complemented by a preparatory course at Lycée Charlemagne.
This person is not in any teams
Cilcare
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases. CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus. CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy. CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring. We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.